ŠTARK, Tibor, Jana RUDÁ, Fabio IANNOTI, Claudio D'ADDARIO, Roberta DI MARCO, Vladimír PEKAŘÍK, Eva DRAŽANOVÁ, Fabiana PISCITELLI, Monica BARI, Zuzana BABINSKÁ, Giovanni GIURDANELLA, Martina DI BARTOLOMEO, Salvatore SALOMONE, Alexandra ŠULCOVÁ, Mauro MACCARRONE, Carsten WOTJAK, Zenon STARČUK, Filippo DRAGO, Raphael MECHOULAM, Vincenzo DI MARZO and Vincenzo MICALE. Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia. Neuropharmacology. Oxford: Pergamon-Elsevier Science LTD, 2019, vol. 146, No 1, p. 212-221. ISSN 0028-3908. Available from: https://dx.doi.org/10.1016/j.neuropharm.2018.11.035.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Peripubertal cannabidiol treatment rescues behavioral and neurochemical abnormalities in the MAM model of schizophrenia
Authors ŠTARK, Tibor (703 Slovakia, belonging to the institution), Jana RUDÁ (203 Czech Republic, guarantor, belonging to the institution), Fabio IANNOTI (380 Italy), Claudio D'ADDARIO (380 Italy), Roberta DI MARCO (380 Italy), Vladimír PEKAŘÍK (203 Czech Republic, belonging to the institution), Eva DRAŽANOVÁ (203 Czech Republic, belonging to the institution), Fabiana PISCITELLI (380 Italy), Monica BARI (380 Italy), Zuzana BABINSKÁ (703 Slovakia, belonging to the institution), Giovanni GIURDANELLA (380 Italy), Martina DI BARTOLOMEO (380 Italy), Salvatore SALOMONE (380 Italy), Alexandra ŠULCOVÁ (203 Czech Republic), Mauro MACCARRONE (380 Italy), Carsten WOTJAK (276 Germany), Zenon STARČUK (203 Czech Republic), Filippo DRAGO (380 Italy), Raphael MECHOULAM (376 Israel), Vincenzo DI MARZO (380 Italy) and Vincenzo MICALE (380 Italy, belonging to the institution).
Edition Neuropharmacology, Oxford, Pergamon-Elsevier Science LTD, 2019, 0028-3908.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30104 Pharmacology and pharmacy
Country of publisher United Kingdom of Great Britain and Northern Ireland
Confidentiality degree is not subject to a state or trade secret
WWW URL
Impact factor Impact factor: 4.431
RIV identification code RIV/00216224:14110/19:00109798
Organization unit Faculty of Medicine
Doi http://dx.doi.org/10.1016/j.neuropharm.2018.11.035
UT WoS 000457663900021
Keywords in English Cannabidiol; Cannabinoid CB1 receptor; MAM model; Schizophrenia
Tags 14110515, 14110516, CF CELLIM, rivok
Tags International impact, Reviewed
Changed by Changed by: Mgr. Tereza Miškechová, učo 341652. Changed: 11/5/2020 12:58.
Abstract
In agreement with the neurodevelopmental hypothesis of schizophrenia, prenatal exposure of rats to the anti mitotic agent methylazoxymethanol acetate (MAM) at gestational day 17 produced long-lasting behavioral alterations such as social withdrawal and cognitive impairment in the social interaction test and in the novel object recognition test, respectively. At the molecular level, an increased cannabinoid receptor type-1 (CB1) mRNA and protein expression, which might be due to reduction in DNA methylation at the gene promoter in the prefrontal cortex (PFC), coincided with deficits in the social interaction test and in the novel object recognition test in MAM rats. Both the schizophrenia-like phenotype and altered transcriptional regulation of CB1 receptors were reversed by peripubertal treatment (from PND 19 to PND 39) with the non-psychotropic phytocannabinoid cannabidiol (30 mg/kg/day), or, in part, by treatment with the cannabinoid CB1 receptor antagonist/inverse agonist AM251 (0.5 mg/kg/day), but not with haloperidol (0.6 mg/kg/day). These results suggest that early treatment with cannabidiol may prevent both the appearance of schizophrenia-like deficits as well as CB1 alterations in the PFC at adulthood, supporting that peripubertal cannabidiol treatment might be protective against MAM insult.
Links
LM2015062, research and development projectName: Národní infrastruktura pro biologické a medicínské zobrazování
Investor: Ministry of Education, Youth and Sports of the CR
LQ1601, research and development projectName: CEITEC 2020 (Acronym: CEITEC2020)
Investor: Ministry of Education, Youth and Sports of the CR
MUNI/A/1132/2017, interní kód MUName: Behaviorální psychofarmakologie a farmakokinetika v preklinickém výzkumu léčiv
Investor: Masaryk University, Category A
3SGA5789, interní kód MUName: PRECIPITATION OF SCHIZOPHRENIA-LIKE PHENOTYPE BY PRENATAL INFLUENCES: ASSESSING THE ROLE OF THE ENDOCANNABINOID SYSTEM (Acronym: ncRNAPain)
Investor: South-Moravian Region, Incoming grants
PrintDisplayed: 22/7/2024 16:17